Drug intelligence / Profile preview

MEVAC MULTI ADENO

Development stage: Unknown
Lead developer: Kemin Industries
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous, Intramuscular

Overview

MEVAC MULTI ADENO is an inactivated tetravalent veterinary vaccine developed by Middle East for Vaccines (MEVAC) to protect poultry against fowl adenovirus (FAdV) infections. The vaccine contains inactivated FAdV antigens from multiple species and serotypes, designed to induce a protective immune response in chickens. It specifically targets diseases such as inclusion body hepatitis (IBH) and hydropericardium hepatitis syndrome (HPS). Administered via subcutaneous or intramuscular injection to chickens from seven days of age, it aims to reduce clinical signs and mortality associated with FAdV in commercial poultry operations.

Brand names: MEVAC MULTI ADENO
Other names: Fowl Adenovirus VaccineMEVAC Fowl Adenovirus Vaccine

Beyond the preview

Go deeper on MEVAC MULTI ADENO.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MEVAC MULTI ADENO.

Explore the full profile